Welcome to our dedicated page for Serina Therapeutics SEC filings (Ticker: SER), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Serina Therapeutics's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Serina Therapeutics's regulatory disclosures and financial reporting.
Serina Therapeutics Chief Scientific Officer exercises and sells options-linked shares. On March 23, 2026, Randall Moreadith exercised stock options for 6,500 shares of common stock at an exercise price of $0.06 per share and then sold the same 6,500 shares in open-market transactions at a weighted average price of $2.8566 per share, with individual sale prices ranging from $2.68 to $3.03. This exercise-and-sell pattern represents a routine liquidity transaction rather than an open-market purchase.
Serina Therapeutics, Inc. entered into a private placement led by director Greg Bailey to raise up to $30 million through common stock and pre-funded warrants priced at $2.25 per share. The first tranche of $15 million closed around March 20, 2026, with a second tranche of up to $15 million anticipated by April 30, 2026.
Investors also receive redeemable warrants covering 50% of purchased shares at an exercise price of $5.00 per share and a four-year term, which, if fully exercised, could add up to $33.3 million in proceeds. Proceeds are intended to fund the SER‑252 Phase 1b registrational study for advanced Parkinson’s disease and related milestones. In connection with the financing, Greg Bailey will serve as Co‑Chairman of the Board, and investors gain the right to designate an additional non‑executive director once specified funding thresholds are met, while certain note funding obligations under an existing senior unsecured convertible promissory note have been removed.
Serina Therapeutics, Inc. Chief Scientific Officer Randall Moreadith exercised stock options for 39,000 shares of common stock at $0.06 per share and immediately sold all 39,000 shares at $2.50 per share in an open-market transaction.
The filing shows this was an exercise-and-sell event, with the reported common stock holdings reduced to 0 shares directly after the sale. The stock options involved were fully vested before exercise.
Serina Therapeutics, Inc. reported an insider equity award to its Chief Scientific Officer, Randall Moreadith. On February 3, 2026, he received a grant of 69,000 stock options with an exercise price of $2.76 per share, each option linked to one share of common stock.
The options were granted at no cost to him and are held as direct ownership. According to the vesting terms, 12/48ths of the options vest 12 months after the vesting commencement date, and the remaining portion vests in equal monthly installments of 1/48th until fully vested. After this grant, he beneficially owns 69,000 derivative securities in the form of these options.
Serina Therapeutics, Inc. reported that senior vice president of CMC & Formulation Tenjarla Srini received a grant of stock options on common stock. The award covers 69,000 stock options with an exercise price of $2.76 per share, dated February 3, 2026, held as direct ownership.
These options vest over time: 12/48ths of the shares vest twelve months after the vesting commencement date, and the remaining 1/48th vests on the same calendar day of each following month until fully vested. Following this grant, Srini beneficially owns 69,000 derivative securities in the form of these options.
Serina Therapeutics, Inc. reported that director Simba Gill received a grant of stock options. On 02/03/2026, he was awarded an option to acquire 92,000 shares of common stock at an exercise price of $2.76 per share, expiring on 02/03/2036.
According to the vesting terms, 12/48ths of the option shares vest twelve months after the vesting commencement date, with the remaining shares vesting in equal 1/48th monthly installments until fully vested, unless the option is earlier terminated under the option agreement.
Serina Therapeutics granted Chief Executive Officer and director Steven A. Ledger a stock option covering 230,100 shares of common stock at an exercise price of $2.76 per share. The option expires on 02/03/2036 and was awarded at a cost of $0 to the recipient.
According to the vesting terms, 12/48ths of the shares vest twelve months after the vesting commencement date, with 1/48th of the shares vesting monthly thereafter until fully vested. Following this grant, Ledger directly holds derivative securities representing 230,100 underlying shares.
Serina Therapeutics, Inc.'s Chief Scientific Officer, Randall Moreadith, reported an option exercise and share sale. On February 2, 2026, he exercised stock options for 6,500 shares of common stock at an exercise price of $0.06 per share and acquired these shares directly.
That same day, he sold 6,500 shares of common stock in a market transaction at a weighted average price of $3.0277 per share, with actual sale prices ranging from $3.00 to $3.05. After the sale, he reported owning 0 shares of common stock from this lot and 313,186 stock options that are fully vested.
Serina Therapeutics is registering 7,722,006 shares of common stock for resale by existing investors, tied to a 2025 senior unsecured convertible note and related warrants. The shares include 3,861,003 conversion shares from the note and 3,861,003 warrant shares.
The company will not receive proceeds from investors’ resale of these shares, though the underlying note provides up to $20 million of funding at 10% interest, convertible at $5.18 per share with warrants exercisable at $5.44. Serina highlights substantial risks, including doubts about its ability to continue as a going concern, a notice from NYSE American over low stockholders’ equity, and early-stage clinical uncertainty. The FDA previously placed a clinical hold on its SER-252 Parkinson’s program, later clearing the IND to allow a Phase 1b registrational study to proceed.